Outbreak of Lassa Fever in Nigeria

Outbreak of Lassa Fever in Nigeria

 “Nigeria’s Lassa fever outbreak has reached record highs with 317 laboratory confirmed cases, according to figures released by the Nigeria Centre for Disease Control (NCDC) this week...”

Cancer research may lose funding

Cancer research may lose funding

GOP lawmakers take aim at @WHO agency supporting #cancer research over Roundup ingredient shown to be #carcinogenic 

A Case for BARDA to Produce Therapeutics

Doctors Without Borders (MSF) recently noted the one of the best products to treat deadly snakebites has ended production and the remaining supply will soon be exhausted. FAV-Afrique can be used to treat bites from ten venomous snakes, and has been a mainstay in sub-Saharan Africa. At the root of this incredible situation is the fact that Sanofi Pasteur had stopped producing FAV-Afrique years before due to cost competitiveness. The World Health Organization (WHO), MSF, and other related organizations knew of this production stoppage and advocated for transfer of IP from Sanofi to another company to continue production. Yet, this life-saving products remains shelved and would be at least a few years from replenishment even under the most ideal circumstances. 

 

In the United States, under Health and Human Services, an organization exists whose charter is to produce late stage therapeutics  -especially in therapeutic areas that Big Pharma has largely exited. In fact, Peptineo had lobbied to employ this same resource to produce a late stage Ebola vaccine that had been shelved. This process was successfully engaged for MAPP Pharmaceuticals (producers of ZMapp) to produce its Ebola antibody cocktail -and BARDA has a pipeline of other products that it is producing. Under BARDA, a virtual pharmaceutical manufacturing capability has been established to take a therapeutic into production and complete all required regulatory milestones for FDA licensure. While BARDA may not be positioned to produce this desperately needed anti-venom, the model for producing late-stage or previously approved regulatory products is worth consideration. Given that modern manufacturing of pharmaceuticals has experienced a significant reduction in infrastructure costs and physical footprints to produce products (example: NNE Pharmaplan flexible manufacturing designs), perhaps the WHO and others should consider establishing rapid manufacturing capabilities similar to BARDA. Not only can products be made, but a streamlined process has also been developed to move products quickly through necessary regulatory efforts. The following links directly to additional background on the incredible stoppage and shelving of the FAV-Afrique anti-venom and is found here

image.jpg

US Preparing for Zika

US Preparing for Zika

The United States of America is preparing for Zika to reach its shores. As it prepares, the CDC has an emergency response group working behind the scenes to anticipate and respond to this emerging health concern.  

 #Zika

#Zika

For more information on what the CDC is doing to prepare for Zika see below... 

 

CDC prepares for Zika

Key Recent Data on Zika Cases in Brazil

Here is a recent update on cases being reported in Brazil on Zika.  The data was compiled by Brazil Ministry of Health and assembled by Ian MacKay, PhD.  

 

 CNS and related effects of Zika

CNS and related effects of Zika

 Confirmed Zika Diagnoses

Confirmed Zika Diagnoses